Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Nan Sethakorn"'
Autor:
Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. Lang
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-13 (2022)
Abstract Introduction PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other components
Externí odkaz:
https://doaj.org/article/b9045af0a9af4371a592c3d1c272ffac
Autor:
Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Camila I. Hernandez, Serena K. Wolfe, Richel D. Mayberry, Hannah M. Krause, Matt Bootsma, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E. Kyriakopoulos, David Kosoff, Xiao X. Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Wei Huang, Himisha Beltran, Toni K. Choueiri, Howard I. Scher, Dana E. Rathkopf, Susan Halabi, Andrew J. Armstrong, David J. Beebe, Menggang Yu, Kaitlin E. Sundling, Mary-Ellen Taplin, Joshua M. Lang
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.Methods We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex
Externí odkaz:
https://doaj.org/article/ec5e2f5145314e94b0c25808c0d5eee0
Autor:
Wade T. Iams, Meridith L. Balbach, Sharon Phillips, Adrian Sacher, Christine Bestvina, Vamsidhar Velcheti, Xiao Wang, Melina E. Marmarelis, Nan Sethakorn, Ticiana Leal, Paul E. Sackstein, Chul Kim, MD Andrew Robinson, Kathan Mehta, Robert Hsu, Jorge Nieva, Tejas Patil, D. Ross Camidge
Publikováno v:
Clinical Lung Cancer. 24:228-234
Autor:
Matthew Bootsma, Rana R. McKay, Hamid Emamekhoo, Rory M. Bade, Jennifer L. Schehr, Matthew C. Mannino, Anupama Singh, Serena K. Wolfe, Zachery D. Schultz, Jamie Sperger, Wanling Xie, Sabina Signoretti, Christos E. Kyriakopoulos, David Kosoff, Edwin J. Abel, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Michael Bassetti, John Floberg, Menggang Yu, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Toni K. Choueiri, Joshua M. Lang, Shuang G. Zhao
Publikováno v:
Journal of Clinical Oncology. 40:3633-3641
PURPOSE Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key imm
Autor:
Nan Sethakorn, Erika Heninger, Matthew T. Breneman, Emma Recchia, Adeline B. Ding, David F. Jarrard, Peiman Hematti, David J. Beebe, David Kosoff
Publikováno v:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 36(10)
The tumor microenvironment (TME) is a complex network of non-malignant cells and stroma that perform a wide array of vital roles in tumor growth, immune evasion, metastasis, and therapeutic resistance. These highly diverse roles have been shown to be
Autor:
Erika Heninger, Morgan D. Kuczler, Nan Sethakorn, David Kosoff, Joshua M. Lang, Kenneth J. Pienta, Peiman Hematti
Publikováno v:
Oncotarget
Bone marrow (BM) is a primary metastatic site in prostate cancer (PC) and bone invasion is considered incurable. T cell-mediated immune surveillance is essential in controlling both tumorigenesis and initiation of metastases. Beside tropism, dissemin
Autor:
Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. Lang
Publikováno v:
Biomarker research. 10(1)
Introduction PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other components includin
Autor:
Bing Yang, Erika Heninger, Leigh Ellis, David Kosoff, David J. Beebe, Kristin N. Carlson, Dustin A. Deming, Joshua M. Lang, Harshitha Gungurthi, Tamara S. Rodems, Anupama Singh, Nan Sethakorn, Cole Gilsdorf, Cheri A. Pasch, David F. Jarrard
Publikováno v:
Medical Oncology (Northwood, London, England)
Prostate Cancer (PC) is a disease with remarkable tumor heterogeneity that often manifests in significant intra-patient variability with regards to clinical outcomes and treatment response. Commonly available PC cell lines do not accurately reflect t
Autor:
Kwangok P. Nickel, Shrey Ramesh, Saahil Javeri, Nitin Somasundaram, Nan Sethakorn, Randall J. Kimple, Andrew M. Baschnagel
Publikováno v:
Cancer Research. 82:207-207
Objective: The MET receptor is mutated in 3-4% and amplified in 1-6% of patients with non-small cell lung cancer. The most common MET mutation is in exon 14, which results in deletion of the intracellular juxtamembrane domain of the receptor, leading
Autor:
Nan Sethakorn, Erika Heninger, Cristina Sánchez-de-Diego, Adeline B. Ding, Ravi Chandra Yada, Sheena C. Kerr, David Kosoff, David J. Beebe, Joshua M. Lang
Publikováno v:
Cancers, Vol 14, Iss 757, p 757 (2022)
Bone metastases represent a lethal condition that frequently occurs in solid tumors such as prostate, breast, lung, and renal cell carcinomas, and increase the risk of skeletal-related events (SREs) including pain, pathologic fractures, and spinal co